University of Geneva

AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
Thursday, March 14, 2024
University of Geneva, Diagnosis, Target, Down syndrome, MSA, Disease, ALS, PD, Safety, Multiple system atrophy, Patient, PET, Research, Geneva University Hospitals, Amyloid beta, MJFF, ABATE, Smith, University, KOL, Doctor of Philosophy, MD, TAR, IND, Medicine, AC, University of Luxembourg, Cognition, DS, Johnson & Johnson, Janssen, Sahlgrenska University Hospital, CHF, Injection, DSMB, University of Gothenburg, Food, RETAIN, Janssen Pharmaceuticals, Nature Communications, Pharmaceutical industry

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We made significant progress in 2023 advancing our three innovative active immunotherapy programs in Phase 2 clinical trials in Alzheimer’s and Parkinson’s diseases.

Key Points: 
  • Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We made significant progress in 2023 advancing our three innovative active immunotherapy programs in Phase 2 clinical trials in Alzheimer’s and Parkinson’s diseases.
  • Six-month Abeta positron emission tomography (PET) imaging results are expected in Q2 2024, and 12-month Abeta-PET data are expected in H2 2024.
  • Comm., 2023) showed that AC Immune’s wholly-owned a-syn-PET tracer ACI-12589 can detect a-syn pathology in multiple system atrophy (MSA) and differentiate MSA from other a-synucleinopathies.
  • PI-2620 was discovered and developed using the Morphomer® platform as part of a research collaboration between AC Immune and Life Molecular Imaging.

Alipay+ and Partner E-Wallets Drive Sustainable Travel in Year-End Global Campaign

Retrieved on: 
Thursday, December 14, 2023
Retail, Technology, Finance, Fintech, Other Travel, Transportation, Apps, Applications, Professional Services, Destinations, Travel, Other Retail, Personal Finance, Vacation, Payments, Mobile, Wireless, King Power, Sustainable Development Goals, Mom, GCash, Tourism, Somatosensory system, Chinese, BNPL, CUHK, Multimedia, Culture, University of Geneva, Ecosystem, SME, TrueMoney, Marketing, Merchant services, Digital, Tsinghua University, University, DAT, TPV, HK, Naukri.com, KakaoPay, Northwestern University in Qatar, ESG, Cryptocurrency, Online shopping, Tutoring, Alipay, University of Hong Kong

Ant International is committed to promoting sustainable and responsible tourism across its Alipay+ markets, with an ESG program closely aligned with the UN Sustainable Development Goals (SDGs).

Key Points: 
  • Ant International is committed to promoting sustainable and responsible tourism across its Alipay+ markets, with an ESG program closely aligned with the UN Sustainable Development Goals (SDGs).
  • The campaign features special offers from Alipay+ and partners to encourage sustainable travel behavior, such as free overseas mobile data packages, in-app discounts across Alipay+’s extensive merchant network, and opportunities to win 100% rebates at partner stores.
  • Dr Cherry Huang, General Manager of Alipay+ Offline Merchant Services, Ant International said, “Our year-end campaign is not just about travel; it’s about making a positive impact.
  • Touch ’n Go eWallet cross-border payments in the Chinese mainland have grown by more than 100% month-on-month in 2023.

Tonix Pharmaceuticals Announces Issuance of EU Patent Covering Intranasal Potentiated Oxytocin (TNX-1900) for the Treatment of Pain

Retrieved on: 
Wednesday, October 4, 2023
University of Geneva, Patent, Insulin resistance, Tonix Pharmaceuticals, Migraine, University, Magnesium, Prader–Willi syndrome, European Patent Office, INSERM, Feeding disorder, Oxytocin, IP, EPO, Patient, European Patent Convention, Pharmaceutical industry

CHATHAM, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that the European Patent Office (EPO) issued European Patent No. 3242676 to the Company on October 4, 2023. The patent, entitled “Magnesium-Containing Oxytocin Formulations and Methods of Use”, claims methods and compositions for treating pain, including migraine headaches, using intranasal magnesium-containing oxytocin formulations. This patent, excluding possible patent term extensions, is expected to provide Tonix with market exclusivity in the member states of the European Patent Office until 2036. The U.S. Patent and Trademark Office (USPTO) has previously issued U.S. Patents No. 9,629,894 and 11,389,473 which are expected to provide market exclusivity in the U.S. until 2036.

Key Points: 
  • CHATHAM, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that the European Patent Office (EPO) issued European Patent No.
  • The patent, entitled “Magnesium-Containing Oxytocin Formulations and Methods of Use”, claims methods and compositions for treating pain, including migraine headaches, using intranasal magnesium-containing oxytocin formulations.
  • This patent, excluding possible patent term extensions, is expected to provide Tonix with market exclusivity in the member states of the European Patent Office until 2036.
  • “We believe this European patent combined with the U.S. issuance provides a strong patent position for TNX-1900 as we move forward in clinical development for the treatment of chronic migraine,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals.

Anavo Therapeutics Strengthens Management Team

Retrieved on: 
Thursday, September 21, 2023
Oncology, Health, Other Science, General Health, Science, Pharmaceutical, Biotechnology, University of Geneva, GSK, University, Therapy, University of California, Irvine School of Physical Sciences, CSO, IGNITE, Draupnir, Coronavirus Scientific Advisory Board, Biochemistry and Cell Biology, Doctor of Philosophy, Bachelor of Science, MS, Cell biology, Patient, Serono, Drug discovery, Biology, University of York, McNulty, Merck, Pfizer, D, Pharmaceutical industry, Medical device, Pregabalin, Syntaxin, Biochemistry, Chemistry

Dr. McNulty will oversee the implementation of Anavo’s strategy from discovery into clinical development and, together with Dr. Quattropani and Anavo’s management team, the continued design of Anavo’s first- and best-in-class phosphatase-targeting allosteric modulators.

Key Points: 
  • Dr. McNulty will oversee the implementation of Anavo’s strategy from discovery into clinical development and, together with Dr. Quattropani and Anavo’s management team, the continued design of Anavo’s first- and best-in-class phosphatase-targeting allosteric modulators.
  • “We are fortunate to welcome Anna and Shaun to the Anavo team at this stage of our company’s growth,” said Birgit Zech, PhD, Chief Executive Officer of Anavo Therapeutics.
  • “Anavo’s IGNITE platform uniquely enables the rapid identification and development of therapeutics targeting phosphatases, initially thought to be undruggable targets,” said Dr. McNulty.
  • “I am excited to join the Anavo team as we continue to accelerate our proprietary portfolio of programs targeting disease-relevant phosphatases toward clinical development and to build out our next-generation approach for phosphatase targeting.”
    Anna Quattropani, PhD, joins Anavo with over 20 years of experience in medicinal chemistry and drug discovery.

AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
Friday, August 4, 2023
University of Geneva, Tau, University, The Michael J. Fox Foundation, Sahlgrenska University Hospital, Luxembourg Centre for Systems Biomedicine, Myawaddy Mingyi U Sa, ABATE, Tax, PET, Financial statement, AC, Gothenburg, Doctor of Philosophy, DS, Down syndrome, Target, University of Gothenburg, AAIC, MD, Patient, Medicine, Polhemus Memorial Clinic, Diagnosis, Poster, AD, FDA, CHF, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, University of Luxembourg, ALS, Food, Conference, Safety, Geneva University Hospitals, D, Pharmaceutical industry, Medical imaging, Fine chemical, Vaccine, Amyloid beta

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We entered the second half of 2023 with strong momentum.

Key Points: 
  • Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We entered the second half of 2023 with strong momentum.
  • The first patient with Parkinson’s disease was dosed in the Phase 2 VacSYn clinical trial evaluating ACI-7104.056, AC Immune’s wholly-owned anti-alpha-synuclein (a-syn) active immunotherapy.
  • The Company’s cash balance provides sufficient capital resources to progress into at least Q3 2024 without considering receipt of potential future milestone payments.
  • G&A Expenditures: G&A decreased by CHF 0.7 million to CHF 3.7 million, mostly due to a decrease in personnel expenses.

EQS-News: Secarna Pharmaceuticals announces publication of new preclinical data showing durable antitumor activity of LNAplus™-based ASOs that both stimulate the innate immune system and suppress PD-L1 expressi

Retrieved on: 
Monday, June 5, 2023
University of Geneva, Asos, DNA, ICIS, Human, University, Therapy, ICI, University of Basel, Neoplasm, DC, TLR9, Immunity, DC3 Music Group, Journal, Patient, Pathology, Mouse, ASO, Immunology, Immunotherapy, B cell, PD-L1, Toll-like receptor 9, Vaccine, Pharmaceutical industry, Cancer

TLR9 signaling is an important innate immune pathway that is relevant as a first-line defense mechanism against pathogens.

Key Points: 
  • TLR9 signaling is an important innate immune pathway that is relevant as a first-line defense mechanism against pathogens.
  • A drawback to this approach is that the TLR9 –mediated immune response is blunted by immediate upregulation of immune checkpoints such as PD-L1.
  • The combined downregulation of PD-L1 expression in a single-molecule approach resulted in exceptional antitumor activity in different tumor models.
  • “Our recently published data demonstrate the potential therapeutic effect of simultaneously targeting TLR9 and PD-L1, key modulators of the innate and adaptive immune system, respectively, with a bimodal ASO.

Kenya at 60: how the British used street names to show colonial power

Retrieved on: 
Thursday, June 1, 2023
People, Nairobi Railway Museum, University, Connacht, Farmer, Legislative council, Duke, Parkland, Research, University of Geneva, Workshop, Name, Recreation, Population, Victoria Street, Cattle, Ngong Road, Koinange Street, Council, Family, Connaught Road, Hunting, General store, Warehouse, African, Queensway, Maasai

Place names, along with other urban symbols, were used as a tool of control over space in many African countries during the colonial period.

Key Points: 
  • Place names, along with other urban symbols, were used as a tool of control over space in many African countries during the colonial period.
  • This strategy was epitomised by the British, who applied it in Nairobi and other parts of Kenya from the late 1800s.
  • Spatially, colonial street names dominated the central part of the city, while African names were used mainly in the peripheral residential neighbourhoods.
  • In early colonial Nairobi, the population was composed mainly of three groups: British, Asians and indigenous Africans.

1. Street numbering of railway depot and campsite

    • However, it soon became a permanent settlement, with the construction of the railway station and residential quarters for railway officers, subordinate workers and Indian labourers (who resided in Coolie Landhies).
    • In the 1899 Uganda Railway Plan for Staff Quarters obtained from the Nairobi Railway Museum, the only roads in with actual names were Station and Workshop roads.
    • The street numbering pointed to the functionality of the railway campsite.

2. A claim to city pioneership

    • The top colonial administrator in Kenya was known as a commissioner which was later replaced by the title governor.
    • The first British administrator was Arthur Henry Hardinge, between 1895 and 1900.
    • Streets named after other “pioneers” included Sadler (now Koinange Street), Elliot (now Wabera Street) and Hardinge (now Kimathi Street).
    • Africans were relegated to mere manual labour and temporary residence in the city.

3. Street names to honour the British political order

    • Later, a street was named Connaught Road in their honour.
    • This led to renaming of many streets after royals, for example Princess Elizabeth Way, Victoria Street, Kingsway and Queensway in Nairobi.
    • Laragh Larsen, a geographer, highlights the linkage between royal power, political and economic power in the “re-placing” of urban symbols.

4. Place names to recreate a ‘British home’

    • A major impetus of the colonial officials for naming places in Nairobi was to create a home away from home.
    • Some of those names have endured on the urban landscape of Nairobi: Hurlingham, Lavington, Riverside, Spring Valley, Westlands, Parklands and Highridge, among others.

Conclusion


    If there’s anything Kenya could learn, it is that a naming landscape should showcase unity in diversity. Streets should honour not just the political elite, but other personalities and events that make up society.

SINGING MACHINE ANNOUNCES NEW CARE-EOKE™ INITIATIVE AND SOCIAL GOOD MISSION ON NATIONAL SING-OUT DAY

Retrieved on: 
Thursday, May 25, 2023
Music, The Singing Machine Company, Singing, University, Learning Unlimited, Autism spectrum, Grey, Anxiety, Workplace, Ageing, Brain, Research, University of Geneva, UNIGE, Health, Patient, Sesame Workshop, Learning, Chronic pain, Mental health, CLU, Nursing, Entertainment, Mental

Fort Lauderdale, FL, May 25, 2023 (GLOBE NEWSWIRE) -- The Singing Machine Company, Inc. (“Singing Machine” or the “Company”) (NASDAQ: MICS), the North American leader in consumer karaoke products, today announced the Company’s new CARE-eokeTM by Singing Machine initiative, and a strategic focus on social impact for children and adults of all ages who would benefit from singing. Singing Machine intends to form a series of collaborative partnerships, to help amplify the diverse emotional and physical health and wellness benefits of karaoke, beginning with formalizing its CARE-eoke by Singing Machine initiative.

Key Points: 
  • Singing Machine intends to form a series of collaborative partnerships, to help amplify the diverse emotional and physical health and wellness benefits of karaoke, beginning with formalizing its CARE-eoke by Singing Machine initiative.
  • Many health sources are reporting that singing has countless health advantages and is not just a fun pastime.
  • Rosenberg is formalizing the new CARE-eoke by Singing Machine social entrepreneurship efforts, which include working to align a series of best-in-class strategic partnerships, creating experiences and social impact storytelling to diverse audiences and stakeholders.
  • “For over four decades Singing Machine has been bringing joy through music to millions of families around the world.

EQS-News: BB BIOTECH AG: Creating blockbuster drugs using algorithms

Retrieved on: 
Wednesday, May 3, 2023
Diamond, Insurance, BB Biotech, Drug development, University, Depression, Therapy, Roche, Cancer, Intelligence, Roivant Sciences, Research, Biomarker, Antibody, University of Geneva, MS, Patient, Risk, Machine learning, Algorithm, Drug discovery, Artificial intelligence, AI, FGFR2, Epidemiology, Neurology, News, Peptide, Data science, Pharmaceutical industry, Cryptocurrency, Biochemistry

Artificial intelligence and machine-learning algorithms are disruptive technologies that are having a two-fold impact on the drug discovery process.

Key Points: 
  • Artificial intelligence and machine-learning algorithms are disruptive technologies that are having a two-fold impact on the drug discovery process.
  • Over the past few years BB Biotech has integrated huge volumes of datasets into its own IT infrastructure, covering a wide range of data types.
  • As for the types of drug classes studied, traditional small molecule drugs clearly predominate, followed by biologics (antibodies and peptides).
  • BB Biotech will be closely monitoring developments in the field of computational biotech during the coming years.

AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
Friday, April 28, 2023
University of Geneva, Vaccine, University, The Michael J. Fox Foundation, Sahlgrenska University Hospital, Bank statement, ABATE, Internet, Neurodegenerative disease, Tax, Personalized medicine, LMI, PET, AC, Gothenburg, Doctor of Philosophy, DS, Down syndrome, TAR, Target, Public expenditure, University of Gothenburg, Investigational New Drug, MJFF, MD, Polhemus Memorial Clinic, CHF, ALS, IND, Diagnosis, Safety, Geneva University Hospitals, D, Pharmaceutical industry, Medical imaging, Cryptocurrency

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “Recent accomplishments reaffirm our industry-leading position in developing vaccines and diagnostics for neurodegenerative diseases supporting the transition to targeted treatment and disease prevention.

Key Points: 
  • Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “Recent accomplishments reaffirm our industry-leading position in developing vaccines and diagnostics for neurodegenerative diseases supporting the transition to targeted treatment and disease prevention.
  • Interim safety and immunogenicity data from ABATE’s AD and DS cohorts are expected in the second half of 2023.
  • PI-2620 is being developed as part of a research collaboration between AC Immune and Life Molecular Imaging.
  • Total cash burn guidance for the full year 2023 remains unchanged ranging from CHF 65 to CHF 75 million.